Enanta Pharmaceuticals, Inc (ENTA)
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs primarily for the treatment of viral infections and liver diseases. Founded in 1994 and headquartered in Watertown, Massachusetts, Enanta specializes in liver health, particularly hepatitis B and C, as well as other viral illnesses. The company's research and development efforts aim to create novel therapies to address unmet medical needs in these areas.
Company News
The FDA has approved a label expansion for AbbVie's Mavyret to include the treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Mavyret has shown a 96% cure rate in an 8-week treatment with mostly mild side effects.
The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.
The World Health Organization said COVID cases were lower overall in the week through June 19, but moved higher in Southeast Asia, the Eastern Mediterranean and the European regions as the BA.4 and BA.5 subvariants continued to take hold over other lineages.